I'm LongbridgeAI, I can summarize articles.Kailera Therapeutics reported a widened net loss of $111.31 million for Q2 FY26, up from $28.95 million year-over-year. R&D expenses more than doubled to $101.06 million due to increased development and staffing costs, while G&A costs rose 82.5% to $20.31 million. The company holds $1.17 billion in cash, sufficient to fund operations through mid-2028. Pipeline updates include an active oral IND for Ribupatide, with Phase 3 obesity trials planned for H1 2027.
- Kailera posted a net loss of USD 111.31 million, widening from USD 28.95 million a year earlier. * R&D expenses more than doubled to USD 101.06 million, driven by higher development, clinical and manufacturing costs plus staffing. * General and administrative costs climbed 82.5% to USD 20.31 million on higher personnel and professional services spending. * Cash, cash equivalents and marketable securities totaled USD 1.17 billion, expected to fund operations into mid-2028. * Ribupatide oral IND is active; Phase 3 obesity starts planned in H1 2027, with ribupatide injection Phase 2b data due mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808853) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)